Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
New England Journal of Medicine · 08.05.2025 · 392 (18) · 1824-1835
DOI: 10.1056/nejmoa2408771 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 08.05.2025. Verfasst von Jakub Svoboda und 33 weiteren Autor:innen. Beteiligte Einrichtung: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Interleukin-18, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: NCI NIH HHS, Hospital of the University of Pennsylvania.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia.
- University of Vermont Medical Center, Burlington.
- Cell Therapy and Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia.
- Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
ORCID-Profile: Elise A Chong, Carl H June
Förderung
- NCI NIH HHS
- Hospital of the University of Pennsylvania
Zitieren
APA
Svoboda, J., Landsburg, D. J., Gerson, J., Nasta, S. D., Barta, S. K., Chong, E. A., Cook, M., Frey, N. V., Shea, J., Cervini, A., Marshall, A., Four, M., Davis, M. M., Jadlowsky, J. K., Chew, A., Pequignot, E., Gonzalez, V., Noll, J. H., Paruzzo, L., …, & June, C. H. (2025). Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. New England Journal of Medicine, 392(18), 1824-1835. https://doi.org/10.1056/nejmoa2408771
Vancouver
Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, et al. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. New England Journal of Medicine. 2025;392(18):1824-1835. doi:10.1056/nejmoa2408771
BibTeX
@article{Svoboda2025,
author = {Svoboda, Jakub and Landsburg, Daniel J and Gerson, James and Nasta, Sunita D and Barta, Stefan K and Chong, Elise A and Cook, Michael and Frey, Noelle V and Shea, Joanne and Cervini, Amanda and Marshall, Amy and Four, Megan and Davis, Megan M and Jadlowsky, Julie K and Chew, Anne and Pequignot, Edward and Gonzalez, Vanessa and Noll, Julia Han and Paruzzo, Luca and Rojas-Levine, Juliana and Plesa, Gabriela and Scholler, John and Siegel, Donald L and Levine, Bruce L and Porter, David L and Ghassemi, Saba and Ruella, Marco and Rech, Andrew and Leskowitz, Rachel M and Fraietta, Joseph A and Hwang, Wei-Ting and Hexner, Elizabeth and Schuster, Stephen J and June, Carl H},
title = {Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {18},
pages = {1824--1835},
doi = {10.1056/nejmoa2408771}
}
EUVIMED